ORMP - Oramed Pharmaceuticals Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.6100
+0.1100 (+3.14%)
As of 2:13PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close3.5000
Open3.5100
Bid3.5600 x 1100
Ask3.6200 x 1100
Day's Range3.5000 - 3.6100
52 Week Range2.7800 - 7.8400
Volume6,542
Avg. Volume79,009
Market Cap62.745M
Beta (3Y Monthly)1.33
PE Ratio (TTM)N/A
EPS (TTM)-0.9300
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.00
Trade prices are not sourced from all markets
  • Oramed to Present at BIO International Convention
    PR Newswire14 days ago

    Oramed to Present at BIO International Convention

    NEW YORK , June 3, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery ...

  • Oramed Completes Patient Recruitment of Phase IIb HbA1c Trial for Oral Insulin Capsule ORMD-0801
    PR Newswire27 days ago

    Oramed Completes Patient Recruitment of Phase IIb HbA1c Trial for Oral Insulin Capsule ORMD-0801

    Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has completed enrollment for its 90-day dose-ranging Phase IIb clinical study of its oral insulin capsule main cohort. Close to 300 patients have now been enrolled. 70% (over 200) of these patients have completed treatment in the study.

  • Zacks Small Cap Researchlast month

    ORMP: Data from Phase 1 Trial of Oral GLP-1 in 2Q19…

    Oramed Pharmaceuticals Inc. (ORMP) is a biotechnology company with a proprietary oral protein delivery platform technology. The lead development candidate is ORMD-0801, an oral insulin, that is currently being tested in both type 1 (T1D) and type 2 diabetics (T2D). The company is also developing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1).

  • Oramed to Present at ThinkEquity Conference
    PR Newswire2 months ago

    Oramed to Present at ThinkEquity Conference

    NEW YORK, April 29, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will participate in the upcoming ThinkEquity Conference on May 2, 2019 in New York City. Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (PODTM) technology is based on over 30 years of research by scientists at Jerusalem's Hadassah Medical Center.

  • Introducing Oramed Pharmaceuticals (NASDAQ:ORMP), The Stock That Slid 60% In The Last Five Years
    Simply Wall St.2 months ago

    Introducing Oramed Pharmaceuticals (NASDAQ:ORMP), The Stock That Slid 60% In The Last Five Years

    While not a mind-blowing move, it is good to see that the Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) share price has gained 10% in the last three months. But that doesn't change the fact that the returns over the last half deca...

  • Oramed to Present at 3rd Annual Clinical Trials Summit
    PR Newswire2 months ago

    Oramed to Present at 3rd Annual Clinical Trials Summit

    NEW YORK, April 11, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will participate in the upcoming 3rd Annual Clinical Trials Summit, taking place on April 29-30, 2019 in Barcelona, Spain. Dr. Miriam Kidron, Chief Scientific Officer of Oramed, will speak about the "Race to Pharmacy", on April 30, 2019. Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection.

  • Oramed Patent Allowed in the U.S. for Oral Exenatide
    PR Newswire2 months ago

    Oramed Patent Allowed in the U.S. for Oral Exenatide

    NEW YORK , April 4, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery ...

  • Oramed to Present at H.C. Wainwright Global Life Sciences Conference
    PR Newswire2 months ago

    Oramed to Present at H.C. Wainwright Global Life Sciences Conference

    Dr. Mark Hasleton, Vice President for Business Development of Oramed, will present a corporate overview on April 8, 2019. Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (POD™) technology is based on over 30 years of research by scientists at Jerusalem's Hadassah Medical Center.

  • Oramed Patent Allowed in the U.S. for Key Aspect of Its Oral Delivery Technology
    PR Newswire3 months ago

    Oramed Patent Allowed in the U.S. for Key Aspect of Its Oral Delivery Technology

    Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (PODTM) technology is based on over 30 years of research by scientists at Jerusalem's Hadassah Medical Center.

  • PR Newswire3 months ago

    Chinese Regulatory Authority Approves IND Application of Oramed's Oral Insulin Capsules

    NEW YORK, March 26, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its Chinese partner, Hefei Tianhui Incubator of Technologies Co., Ltd. ("HTIT"), has reached the significant regulatory milestone of approval of an investigational new drug application ("IND") for two doses of its oral insulin (ORMD-0801).  The approval of the IND by the Center For Drug Evaluation of the China National Medical Products Administration ("NMPA", formerly the CFDA) of the oral insulin paves the way for the start of clinical trials in China. "We are pleased that the Chinese regulatory authorities have approved the IND, as it sets a clear path forward for approval of oral insulin in China, bringing oral insulin closer to becoming a reality in the Chinese market," stated Oramed CEO Nadav Kidron.

  • Does The Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Share Price Tend To Follow The Market?
    Simply Wall St.4 months ago

    Does The Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Share Price Tend To Follow The Market?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Anyone researching Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) might Read More...

  • Oramed to Present at BIO CEO & Investor Conference
    PR Newswire4 months ago

    Oramed to Present at BIO CEO & Investor Conference

    Nadav Kidron, Chief Executive Officer of Oramed, will present a corporate overview on February 12, 2019. Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection.

  • Zacks Small Cap Research5 months ago

    ORMP: Multiple Catalysts in 2019…

    In Jan. 2019, Oramed Pharmaceuticals, Inc. (ORMP) filed form 10-Q with financial results for the first quarter of fiscal year 2019 that ended Nov. 30, 2018. For the three months ending Nov. 30, 2018, the company reported revenues of $0.67 million, compared to $0.61 million for the three months ending Nov. 30, 217. The increase was mostly due to increased clinical trial expenses.

  • Oramed Initiates Phase I Oral GLP-1 Study Under IND
    PR Newswire5 months ago

    Oramed Initiates Phase I Oral GLP-1 Study Under IND

    JERUSALEM, Jan. 22, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has begun recruitment for its Phase 1 pharmacokinetic (PK) study for ORMD-0901, its oral GLP-1 capsule. This is the first study of ORMD-0901 under Oramed's existing FDA Investigational New Drug application (IND). In a prior Phase 1 study (in Israel) on type 2 diabetic patients, Oramed's ORMD-0901 capsule was well tolerated and showed encouraging efficacy.

  • Oramed Pharmaceuticals' CEO Letter to Shareholders
    PR Newswire5 months ago

    Oramed Pharmaceuticals' CEO Letter to Shareholders

    JERUSALEM , Jan. 15, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ) Dear Shareholders, We opened the year 2019 with the announcement of our receipt of a ...

  • Oramed Receives Additional $3 Million Milestone Payment from HTIT
    PR Newswire5 months ago

    Oramed Receives Additional $3 Million Milestone Payment from HTIT

    JERUSALEM, Jan. 9, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has received a milestone payment of $3 million from Hefei Tianhui Incubator of Technologies Co. Ltd. (HTIT). This milestone is part of a previously-announced license and investment agreement between Oramed and HTIT. "China is currently the largest single diabetes population in the world," stated Oramed CEO Nadav Kidron.

  • Zacks Small Cap Research6 months ago

    ORMP: Two Studies Ongoing for ORMD-0801 with Data Readouts in 2019…

    In Nov. 2018, Oramed Pharmaceuticals Inc. (ORMP) filed form 10-K with financial results for fiscal year 2018 that ended Aug. 31, 2018. The company reported revenues of $2.449 million, which was very similar to the $2.456 million reported in fiscal year 2017. Cost of revenues in fiscal year 2018 decreased to income of $86,000 compared to cost of $187,000 in fiscal year 2017.

  • Is Oramed Pharmaceuticals Inc’s (NASDAQ:ORMP) CEO Paid Enough Relative To Peers?
    Simply Wall St.7 months ago

    Is Oramed Pharmaceuticals Inc’s (NASDAQ:ORMP) CEO Paid Enough Relative To Peers?

    Nadav Kidron has been the CEO of Oramed Pharmaceuticals Inc (NASDAQ:ORMP) since 2006. First, this article will compare CEO compensation with compensation at similar sized companies. Next, we’ll consider growth Read More...

  • Zacks Small Cap Research7 months ago

    ORMP: Transferring Coverage; Multiple Clinical Readouts for Oral Protein Delivery Technology Over Next 12-18 Months

    Oramed Pharmaceuticals Inc. (ORMP) is a biotechnology company with a proprietary oral protein delivery platform technology. The lead development candidate is ORMD-0801, an oral insulin, that is currently being tested in both type 1 (T1D) and type 2 diabetics (T2D). The clamp study is enrolling T1D patients with HbA1c levels ≤ 10% between the ages of 18-70 The clamp study was originally developed in 1979 as a means of testing how well a patient metabolizes glucose and their insulin sensitivity (DeFronzo et al., 1979).

  • Oramed Completes Over 50% Randomization in Its Pivotal 90-Day Clinical Study
    PR Newswire7 months ago

    Oramed Completes Over 50% Randomization in Its Pivotal 90-Day Clinical Study

    NEW YORK, Nov. 13, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has successfully randomized more than 50% of the expected 285 patients for its 90-day dose-ranging Pivotal Phase 2b clinical study of its oral insulin capsule, ORMD-0801. "We are pleased that the pace of patient enrollment is in line with our expectations and look forward to data release in the coming year," stated Oramed CEO, Nadav Kidron. Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection.

  • Oramed to Present at the Tides Europe 2018 Conference
    PR Newswire7 months ago

    Oramed to Present at the Tides Europe 2018 Conference

    NEW YORK, Nov. 5, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com),  a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Tides Europe 2018 Conference, EuroPeptides Track, taking place on November 6-9, 2018 in Amsterdam.  Dr. Miriam Kidron, Oramed's Chief Scientific Officer, will speak about "Oral Insulin: An Impending Reality?" at the conference on November 7, 2018. Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (PODTM) technology is based on over 30 years of research by top scientists at Jerusalem's Hadassah Medical Center.

  • Oramed to Present at Cardiometabolic Health Congress
    PR Newswire8 months ago

    Oramed to Present at Cardiometabolic Health Congress

    Now in its 13th year, the Cardiometabolic Health Congress is the largest, US-based, multidisciplinary conference focused solely on the management of cardiometabolic risk and the prevention of cardiovascular and metabolic disease. Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (PODTM) technology is based on over 30 years of research by scientists at Jerusalem's Hadassah Medical Center.

  • Oramed Enrolls First Patient in Its Clinical Study for Oral Insulin in the Treatment of NASH
    PR Newswire8 months ago

    Oramed Enrolls First Patient in Its Clinical Study for Oral Insulin in the Treatment of NASH

    NEW YORK, Oct. 4, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has enrolled the first patient in an exploratory clinical study of its oral insulin capsule, ORMD-0801, in the treatment of nonalcoholic steatohepatitis (NASH). The three-month treatment study, recently approved by Israel's Ministry of Health, will assess the effectiveness of ORMD-0801 in reducing liver fat content, inflammation and fibrosis in patients with NASH. Data from preclinical studies and clinical studies of ORMD-0801 demonstrate Oramed's oral insulin capsule has the potential to reduce inflammation of the liver.

  • Is Oramed Pharmaceuticals Inc’s (NASDAQ:ORMP) Balance Sheet Strong Enough To Weather A Storm?
    Simply Wall St.9 months ago

    Is Oramed Pharmaceuticals Inc’s (NASDAQ:ORMP) Balance Sheet Strong Enough To Weather A Storm?

    The direct benefit for Oramed Pharmaceuticals Inc (NASDAQ:ORMP), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-offRead More...

  • Oramed Receives FDA Clearance for IND Application for Its Oral GLP-1 Analog Capsule
    PR Newswire9 months ago

    Oramed Receives FDA Clearance for IND Application for Its Oral GLP-1 Analog Capsule

    NEW YORK, Sept. 17, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for human trials of its oral GLP-1 analog capsule ORMD-0901. In a prior Phase 1 study on type 2 diabetic patients, Oramed's ORMD-0901 capsule was well tolerated and showed encouraging efficacy, including reducing blood sugar levels following a standard meal as compared to a placebo. Oramed's planned Phase 1 pharmacokinetic (PK) study is a fully-randomized, single-blind, placebo-controlled 4-way crossover study which will evaluate safety in addition to the pharmacokinetics of ORMD-0901 compared to placebo and to open label Byetta®, a GLP-1 analog currently on the market, in up to 15 healthy subjects.